The VE-BASKET study investigating the efficacy of the BRAF inhibitor vemurafenib against BRAF V600E-mutant cancers demonstrated that efficacy varied by histologic subtypes in patients with BRAF V600E-mutant brain tumors [17], suggesting that some BRAF V600E-mutant tumors have multiple concurrent drivers. The gene discussed is BRAF; the disease is cancer.